MSLN and neoplasm: We previously reported that shed mesothelin (MSLN) in blood circulation negatively affected the tumor targeting of amatuximab labeled with 111In or 64Cu by increasing its liver and spleen uptakes while decreasing its blood retention and tumor uptake when the injection dose of amatuximab was not sufficient to saturate the shed MSLN in blood circulation [5, 6].